Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Currently Reading
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work

A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Centerís Postdoctoral Health Policy Fellow.


A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Centerís Postdoctoral Health Policy Fellow.

Transcript (slightly modified)

Is a one-size-fits-all approach to value possible in US healthcare?

Itís not possible to have a one-size-fits-all approach to value assessment in the US healthcare system. We need a tailored approach, and to do so this means that we need to understand, define, and measure value accurately, and then tailor our approach to the stakeholder, to the health condition, and to the sub-population. This is imperative because there are substantial repercussions for reimbursement, patient access, and patient outcomes. Itís also important that we have a tailored approach because this is what will help drive innovation and make sure that future therapies are developed with what the patients want in mind.

What are the challenges of dealing with a pluralistic approach to value assessment?

The challenges of pluralistic approach to value assessment are that we have to account for individual preferences while making decisions at a population level. This is extremely complex to implement in a real-world application. It means highly sophisticated formulary designs and highly sophisticated reimbursement arrangements.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!